Kaleido Biosciences Inc. is a clinical-stage biotechnology company focused on developing microbiome metabolic therapies aimed at treating a broad spectrum of diseases. Founded in 2015 and headquartered in Lexington, Massachusetts, the company innovates in the emerging field of microbiome science, utilizing a proprietary platform called Microbiome Metabolic Therapies (MMT™). This platform leverages a diverse library of over 1,500 synthetic glycans that are orally administered, specifically designed to influence the metabolic output and composition of the gut microbiome without introducing live bacteria. Kaleido Biosciences targets multiple therapeutic areas, including urea cycle disorders, ulcerative colitis, hepatic encephalopathy, and COVID-19, as well as chronic conditions like multidrug-resistant infections, chronic kidney disease, cardiovascular disease, metabolic syndrome, immuno-oncology, and inflammatory bowel disease. The company actively collaborates with leading research institutions and pharmaceutical partners, such as the Institute Gustave Roussy, Washington University, and Janssen, to advance its pipeline. Kaleido’s differentiated approach, robust intellectual property portfolio, and strategic partnerships distinguish it within the rapidly evolving microbiome therapeutics sector, emphasizing the potential of the microbiome as a novel target for disease management and health improvement.